Ratings Akeso, Inc.

Equities

9926

KYG0146B1032

Delayed Hong Kong S.E. Other stock markets 01:31:36 2024-04-19 am EDT			5-day change	1st Jan Change
43.45 ^HKD	-4.30%		-12.22%	-6.36%

Mar. 22	Akeso to Raise Over HK$1 Billion Via Share Sale	MT
Mar. 19	Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The group shows a rather high level of debt in proportion to its EBITDA.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AKESO, INC.	-6.36%	5.02B	B-
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B	B+
ARGENX SE	-0.44%	21.66B	B
BIONTECH SE	-18.35%	20.77B	B+
GENMAB A/S	-7.45%	18.53B	A-
WUXI APPTEC CO., LTD.	-40.31%	16.91B	A-
BEIGENE, LTD.	-26.84%	13.79B	B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B	C+
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes